#United States #San Francisco #Medical Trials #Neurotronic #Neuviant

Neurotronic Unveils Clinical Breakthrough for Type 2 Diabetes and Hypertension

In an unprecedented move, Neurotronic, Inc. has announced upcoming presentations detailing the initial clinical outcomes from its groundbreaking Neuviant™ Multi-organ Denervation (MDN) therapy. This innovative approach seeks to tackle the persistent challenges posed by type 2 diabetes mellitus (T2DM) and hypertension (HTN), two chronic conditions that affect millions worldwide and are notoriously difficult to manage.

Overview of the Research

The findings, derived from two significant clinical trials—NECTAR III and NECTAR IV—are set to be showcased at the prestigious Transcatheter Cardiovascular Therapeutics (TCT) 2025 meeting in San Francisco. This will be the first time the medical community will gain insight into the effects of multi-organ denervation on these conditions. The therapy targets overactive sympathetic nerve pathways, which play a crucial role in regulating both blood sugar levels and blood pressure.

Trial Details

The NECTAR III study involved participants who were diagnosed with both T2DM and HTN but had limited success in controlling their symptoms despite existing medications. Meanwhile, NECTAR IV required participants to have both conditions poorly managed. The primary focus of both trials was on the safety and efficacy of the investigational Neuviant MDN system, which utilizes a catheter to administer dehydrated ethanol (referred to as Simpathol™) to the hepatic and renal areas, effectively disrupting the overactive nerve pathways.

Presentation Schedule

TCT 2025
Location: Moscone Center, San Francisco, California
Date: October 25-28, 2025
NECTAR IV Presentation
Title: Multi-organ Arterial Denervation for T2DM and Its Comorbidities
Presenter: Professor Dr. Horst Sievert, Frankfurt, Germany
Session: Best Endovascular Intervention Abstracts
Date & Time: October 26, 12:10 PM - 12:20 PM

NECTAR III Presentation
Title: Multi-organ Ethanol Denervation for T2DM and Hypertension
Presenter: Dr. Ajay Kirtane, Columbia University Medical Center, New York
Session: Innovation Session on Percutaneous Denervation
Date & Time: October 27, 7:49 AM - 8:00 AM

Significance of the Findings

These presentations not only mark a significant milestone for Neurotronic but also provide hope for patients suffering from T2DM and HTN. The innovative Neuviant MDN procedure aims to provide a new avenue for treatment, which could lead to better management of these conditions and drastically improve quality of life for many individuals.

Future Implications

The potential of this therapy is immense. As a novel approach, the Neuviant system may redefine how healthcare providers manage metabolic and cardiovascular diseases, specifically in patients who have been unresponsive to existing treatments. With these results soon to be unveiled at a major global symposium, the anticipation surrounding neurodegenerative intervention and its role in chronic disease management continues to build.

Neurotronic, founded in 2015, remains at the forefront of developing solutions for complex cardiovascular and metabolic diseases. Those interested in learning more about the Neuviant MDN therapy or potential future clinical trials can reach out via email protected] or visit their official website at [neurotronic.com.